When the Plan Breaks: Nine Things That Go Wrong on a Medical Trip to China
A step-by-step troubleshooting guide for foreign patients in China — what fails at each stage, why it happens, and the specific action that recovers it.
Read Article →Expert guides, cost comparisons, and patient stories to help you make informed decisions about healthcare in China
9 chapters. Everything from hospital selection to recovery at home. Free.
Explore our comprehensive guides on medical procedures, costs, and hospitals in China.
Medical procedures you can only get in China — or get dramatically cheaper, faster, and at higher volume than anywhere else.
Three categories where China is genuinely ahead of the world — not just cheaper.
Acupuncture, herbal medicine, moxibustion, cupping, baduanjin — proven in clinical trials, integrated with Western care at top hospitals.
7 approved CAR-T therapies (more than US/EU), world's largest CRISPR pipeline, broader stem cell access through Boao Lecheng.
Ophthalmology, orthopedics, cardiac surgery, microsurgery, IVF — where Chinese hospitals do the most cases in the world.

A step-by-step troubleshooting guide for foreign patients in China — what fails at each stage, why it happens, and the specific action that recovers it.
Read Article →
When a pancreatic body tumour encases the splenic vein, standard spleen-preserving surgery may not be possible. A Xi'an team describes a third route — and names it.
Read Article →If low kidney function or an iodine allergy rules out standard angiography, carbon dioxide angiography may be the way in. What Chinese vascular centres actually do, where CO₂ stops working, and what to send first.
Read Article →Graft survival, donor planning, hairline design and who does the work decide a hair transplant result — not the technique's brand name. A quality-first guide for China.
Read Article →Wuhan's Union Hospital says a child lived 485 days on a fully magnetically levitated biventricular pump before receiving a donor heart. What the hospital claimed, and what has not been verified.
Read Article →A public hospital in Beidaihe has been treating patients with qigong since the 1950s. What it is, what it is not, and who it is actually for.
Read Article →China's obesity drug candidates now report around 19% weight loss in Phase III. The 2026 data, tolerability, the China-first mazdutide, and what treatment costs.
Read Article →Weight-loss surgery in China: how surgeons choose between sleeve gastrectomy, gastric bypass and mini-bypass, what each costs, and what happens after.
Read Article →Pluvicto is licensed in China — the only PSMA-targeted radioligand therapy approved here. What it costs, who qualifies, and the path from PSMA PET scan to first infusion.
Read Article →Colorectal cancer in China: colectomy for colon cancer, chemoradiation before surgery for rectal cancer, and when a permanent stoma is unavoidable. Costs, hospitals, and what the tests decide.
Read Article →Heart valve disease in China: repair vs replacement, mechanical vs biological valves, and open surgery vs TAVR. Costs, hospitals, and how the choice is made.
Read Article →Stomach cancer treatment in China: partial or total gastrectomy, perioperative chemotherapy, and systemic therapy by stage. Costs, hospitals, and how the plan is set.
Read Article →Stroke rehabilitation in China: why the first three to six months matter most, what an inpatient programme involves, where TCM fits, and what it costs.
Read Article →Breast cancer treatment in China: surgery and reconstruction for early stage, neoadjuvant therapy for locally advanced. Costs, hospitals, and how subtype decides.
Read Article →DC therapy is not routine care in mainland China. The only two legal routes, the 2026 rule changes, and how to spot a clinic selling a cure.
Read Article →Cervical cancer in China: surgery for early stage, chemoradiation plus brachytherapy for locally advanced disease. Costs, top hospitals, and the staging path.
Read Article →Low EF (≤35%) and refractory heart failure: how doctors choose CRT, ICD, CCM, CABG, valve repair, LVAD or transplant — costs and the decision path.
Read Article →Independent matching, a free cost calculator, 52 verified hospital pages, three service tiers — how we help you choose a hospital in China.
Read Article →1.28 million international patients, CAR-T at a third of US prices, 48-hour workups. Why foreigners fly to China for cancer care in 2026 — data, real cases, costs.
Read Article →A New Zealand man became the first international patient to complete satri-cel, China's world-first solid-tumor CAR-T. The real case, timeline, and how to apply.
Read Article →China's flagship device expo wrapped in Beijing: surgical robotics, AI diagnostics, high-end imaging — and why made-in-China technology keeps treatment affordable.
Read Article →The world's first solid-tumor CAR-T targets CLDN18.2 in advanced gastric cancer. Lancet CT041-ST-01 data, who qualifies, the real risks, and how to apply in China.
Read Article →China's only NMPA-approved oncolytic virus fights cold tumors: how the engineered adenovirus works, ASCO 2024 evidence, safety, and how international patients can access it.
Read Article →BCMA CAR-T for relapsed/refractory multiple myeloma in China: $89K-$151K commercial, $30K-$80K trials. Approved products, top hospitals, waiting time — 2026 guide.
Read Article →A Lahore hospital rebuilt a 26-year-old's hip with a Chinese 3D-printed pelvic implant after chondrosarcoma. Why China leads custom implant surgery — and how international patients access it.
Read Article →Indonesia's BPOM and China's NMPA are renewing their drug-regulation MoU, covering CAR-T (ATMP), clinical trials and traditional medicine. What this means for Indonesian patients heading to China.
Read Article →Shanghai startup StairMed unveiled a vein-based brain implant that could be placed in 10 minutes, while China already holds the world's first approved invasive BCI. What international patients should know.
Read Article →NMPA cleared TransThera's tinengotinib (Yochanra) for bile duct cancer that stopped responding to FGFR inhibitors — a world first, with 28% ORR and an 8.5-month median duration of response from the FIRST-08 trial.
Read Article →China approved Leads Biolabs' Opamtistomig (LBL-024) PD-L1 × 4-1BB bispecific for combination trials in MSS/pMMR metastatic colorectal cancer — the 95% of CRC patients who do not respond to standard checkpoint inhibitors.
Read Article →Hainan's Boao Lecheng pilot zone now offers 600+ drugs, devices and therapies approved for the first time in China, added a Korean aesthetic hospital, and runs TCM wellness programs. Here is what international patients can access.
Read Article →Start with a free case review and get guidance on the right hospital and package for your situation.
Start Free Case ReviewFinding the right hospital in China can be overwhelming. Let us help — free, no commitment.
⏳ Most cases get a hospital match within 24 hours